Data from St. Jude Medical’s ASSERT Implantable Device Monitoring Study Published in <I>New England Journal of Medicine</I>

St. Jude Medical, a global medical device company, announced the publication of results from the ASSERT cohort study in the New England Journal of Medicine (NEJM). The ASSERT study, or ASymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial, was designed to determine whether the detection of arrhythmias using pacemaker-based diagnostics predicts an increased risk of stroke in elderly, hypertensive patients without any history of atrial fibrillation (AF). The study results, previously presented at an American Heart Association Scientific Sessions meeting, found that pacemaker patients who have no history of atrial tachycardia (AT) or AF, but do have device-detected arrhythmias, are approximately 2.5 times more likely to have a stroke than patients who do not have device-detected arrhythmias. The trial was sponsored by St. Jude Medical and was conducted by the Population Health Research Institute of McMaster University and Hamilton Health Sciences in Hamilton, Canada. “Approximately 85 percent of atrial arrhythmias documented in the study were picked up only by the pacemaker, proving the device plays a very significant role in identifying patients with a higher risk of stroke,” said Dr. Jeff S. Healey, principal investigator for the arrhythmias program at the Population Health Research Institute. “This monitoring technology is a built-in diagnostic tool and a huge value-add to further assist physicians in properly treating their patients.” The study included 2,580 pacemaker and ICD patients over the age of 65 with hypertension and no history of AF. Subclinical (non-symptomatic) atrial tachyarrhythmias detected by implanted devices occurred in over 10 percent of patients at three months. The risk of systemic embolism (or stroke) associated with non-symptomatic atrial tachyarrhythmias was 13 percent. The diagnostic data and alerts available through St. Jude Medical implantable devices allow physicians and patients to be notified whenever a patient experiences significant atrial arrhythmias (abnormal heartbeats) in the heart's upper chambers, such as AT or AF. “The publication of these findings reminds us how important it is to identify patients with an increased risk of stroke. Diagnostic tools and remote monitoring capabilities already found in St. Jude Medical pacemakers and ICDs make it easier for physicians to capture information to manage AT and AF even when the arrhythmias are not accompanied by symptoms,” said Dr. Mark Carlson, chief medical officer and senior vice president of research and clinical affairs for the St. Jude Medical Cardiac Rhythm Management Division. “St. Jude Medical is committed to providing our customers with clinically relevant information that allows them to deliver more timely and effective care to patients around the world.”